News

The company expects to recruit around 1700 patients to evaluate the effectiveness of NB-001 at 72 clinical sites. The patient recruitment will be completed in 2012. NanoBio Clinical

3Me is a brand development company that operates two subsidiaries, 3Me Media and Adia Nutrition. Adia said its chewable probiotics contain 1 billion bacteria per serving and are

SCENESSE, an injectable implant formulation of the drug afamelanotide, administered every 60 days, mimics the body’s natural ability to activate melanin in the skin. In the pre-submission meeting

Cinryze received FDA approval for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. With this agreement, ViroPharma has received exclusive license to C1

The increase in revenue was primarily due to an increase in revenue from the company’s contract with the National Institute of Allergy and Infectious Diseases (NIAID) of $2.7m

The decision to restart the oral solid dose products to US was based on the US Food and Drug Administration’s (FDA) decision to lift its import alert at

The tie up is expected to advance the use of stem cells for cell therapies and research. Sistemic CEO Jim Reid said they have been using SistemQC microRNA

Vemurafenib, a ‘BRAF-inhibitor,’ is designed to selectively target and inhibit a mutated form of the BRAF protein, a component of the RAS-RAF pathway involved in normal cell growth

NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials Th company intends to recruit around 100-200 patients who have already participated